Boston Scientific Corporation
BSX
Classifica tra le azioni
#409
Questa descrizione dell'azienda è disponibile solo in inglese.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Prezzo delle azioni
$41.88
Ultima sincronizzazione: 2026-10-30
Capitalizzazione di mercato
$60.69B
Variazione (1 giorno)
-1.89%
Variazione (1 anno)
-58.42%
Paese
US
Dati azionari: Financial Modeling Prep·Aggiornato il ·Non è una consulenza finanziaria·Come lo calcoliamo
Scambia Boston Scientific Corporation (BSX)
Categoria
Healthcare
Utile per Boston Scientific Corporation (BSX)
Utile nel Sep 2026 TTM: $3.66B
Secondo gli ultimi rapporti finanziari di Boston Scientific Corporation, gli utili attuali della società sono $3.66B. Nel 2025, la società ha registrato un utile di $3.39B, un aumento rispetto a agli utili del 2024, che erano di $2.28B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Boston Scientific Corporation dal 2000 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Variazione |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Paese |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Domande e risposte: l'utile netto di Boston Scientific Corporation
Qual è l'utile netto di Boston Scientific Corporation?
Secondo gli ultimi dati (set 2026), l'utile netto di Boston Scientific Corporation negli ultimi dodici mesi è pari a $3.66B.
Qual era l'utile netto di Boston Scientific Corporation nel 2025?
Nel 2025, l'utile netto di Boston Scientific Corporation era di $3.39B, con una crescita pari a 48.33% rispetto al 2024 ($2.28B).
Che andamento ha avuto l'utile netto di Boston Scientific Corporation dal 2020?
Dal 2020 al 2025, l'utile netto di Boston Scientific Corporation ha toccato il valore massimo nel 2025 ($3.39B) e il minimo nel 2020 ($-79.00M).
Come si posiziona l'utile netto di Boston Scientific Corporation rispetto ad aziende simili?
Per Boston Scientific Corporation, l'utile netto ($3.66B) supera i valori di 2 delle 5 aziende simili elencate sopra. Tra queste, il valore più alto è quello di Medtronic plc ($6.60B).